Wells Fargo & Company MN lessened its stake in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 27.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 195,132 shares of the biopharmaceutical company’s stock after selling 74,745 shares during the period. Wells Fargo & Company MN owned 0.42% of Bellicum Pharmaceuticals worth $332,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its position in Bellicum Pharmaceuticals by 78.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 12,567 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 5,544 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Bellicum Pharmaceuticals in the 2nd quarter valued at about $233,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Bellicum Pharmaceuticals by 98.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock valued at $3,580,000 after acquiring an additional 1,044,811 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its holdings in Bellicum Pharmaceuticals by 98.5% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock valued at $3,580,000 after acquiring an additional 1,044,811 shares during the last quarter. Hedge funds and other institutional investors own 52.21% of the company’s stock.
Shares of NASDAQ BLCM opened at $0.82 on Wednesday. Bellicum Pharmaceuticals Inc has a twelve month low of $0.78 and a twelve month high of $5.95. The company has a current ratio of 2.67, a quick ratio of 2.67 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $37.93 million, a price-to-earnings ratio of -0.34 and a beta of 1.52. The firm has a 50-day moving average of $1.08 and a two-hundred day moving average of $2.04.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.04). Bellicum Pharmaceuticals had a negative net margin of 4,081.44% and a negative return on equity of 169.33%. The business had revenue of $1.39 million during the quarter, compared to analyst estimates of $0.23 million. As a group, research analysts predict that Bellicum Pharmaceuticals Inc will post -2.12 earnings per share for the current year.
In other Bellicum Pharmaceuticals news, CEO Richard A. Fair purchased 40,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of $1.25 per share, with a total value of $50,000.00. Following the acquisition, the chief executive officer now owns 66,561 shares of the company’s stock, valued at $83,201.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders acquired a total of 68,000 shares of company stock valued at $79,640 over the last three months. 2.64% of the stock is owned by corporate insiders.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. ValuEngine raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
Bellicum Pharmaceuticals Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.
See Also: Capital Gains
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.